Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

November 01, 2010 (Vol. 30, No. 19)

Exploiting HDAC Inhibition

Cancer and Metabolic Diseases Represent Promising Applications

  • Histone deacetylases (HDACs) are emerging as exciting new targets for drug development, particularly for cancer and metabolic diseases. Because they exert control over gene transcription and cell-cycle progression, they represent a novel approach for epigenetic therapeutic intervention. The first such agent was approved by the FDA in 2006 ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.